Medicine for combined use in cancer treatment
US11628199B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2018 |
| Grant date | Apr 18, 2023 |
| Priority date | — |
| Expiry date | Nov 25, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effects of synergistic interaction, which thus overcome the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.